Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
J BUON ; 14 Suppl 1: S153-7, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19785058

ABSTRACT

Lung cancer, one of the leading causes of cancer death in the developed world, presents with a poor 5-year survival, despite improvements in conventional treatments such as surgery, radiotherapy and chemotherapy. Lung cancer-directed immunotherapy promises to harness the body's ability to mount antitumor immune responses and destroy cancer cells. Improving our understanding of tumor biology and the host immune response promises to have a positive impact on the development of novel therapeutic strategies for this disease. This article will present our current understanding on immunotherapy from the perspective of the CD8+ cytolytic T cell response in lung cancer and how elucidation of the mechanisms that affect T-cell memory lineage commitment could improve the outcome of current immunotherapeutic attempts.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/therapeutic use , Immunotherapy/methods , Lung Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , Antigens, Neoplasm/immunology , Humans , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Reference Values , Survival Rate
2.
Immunol Cell Biol ; 85(1): 55-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17130900

ABSTRACT

Cancer immunosurveillance representing, till recently, the explanatory framework relating cancer and the immune system, does not convincingly explain tumor escape. At the beginning of the decade, a new theory emerged, namely the immunoediting theory, and it comprehensively defines the role of the immune system in carcinogenesis. The core of this theory embraces the concept that the immune system on the one hand protects the body from cancer and on the other it shapes the immunogenicity of these cancers, thus presents a persuasive rationalization of the resistance of tumors against the immune response. With the immune system playing, in this context, such a pivotal role in shaping the tumor immune profile and in subsequent oncogenesis, it seems rather paradoxical to accept the immunocompetent host's immune system as a constant moiety. While DNA mutations of immune genes create a rather polymorphic condition, their frequency is much lower than that of other genetic events. Of these, epigenetic alterations give rise to new epialleles, which can reach up to 100% per locus. Bearing in mind that cancer is characterized by a tremendous amount of epigenetic aberrations, in both gene and global level, it is reasonable to postulate that, for the same unknown causes, analogous aberrations could affect the immune genes. Should this be the case, the relation between oncogenesis and the immune system appears much more dynamic and complex. Such an immunoepigenetic approach to carcinogenesis could improve our understanding of a series of common cancer-related aspects, such as environmental risk factors, effectiveness of demethylating agents, failure of current immunotherapies, etc. Moreover, this immunoepigenetic paradigm will take the current perception of the immune system and cancer interrelation further and beyond, constituting that the immunoresistant cancer cell phenotype is not shaped by the immune system acting as a steady and rigid evolutionary pressure, but rather as an extremely dynamic variable.


Subject(s)
Epigenesis, Genetic/immunology , Immunologic Surveillance , Neoplasms/immunology , Antigens, Neoplasm , Humans , Immunotherapy , Neoplasms/genetics , Neoplasms/therapy
3.
Proc Natl Acad Sci U S A ; 98(18): 10290-5, 2001 Aug 28.
Article in English | MEDLINE | ID: mdl-11517302

ABSTRACT

Vaccination of melanoma patients with tumor-specific antigens recognized by cytolytic T lymphocytes (CTL) produces significant tumor regressions in a minority of patients. These regressions appear to occur in the absence of massive CTL responses. To detect low-level responses, we resorted to antigenic stimulation of blood lymphocyte cultures in limiting dilution conditions, followed by tetramer analysis, cloning of the tetramer-positive cells, and T-cell receptor (TCR) sequence analysis of the CTL clones that showed strict specificity for the tumor antigen. A monoclonal CTL response against a MAGE-3 antigen was observed in a melanoma patient, who showed partial rejection of a large metastasis after treatment with a vaccine containing only the tumor-specific antigenic peptide. Tetramer analysis after in vitro restimulation indicated that about 1/40,000 postimmunization CD8(+) blood lymphocytes were directed against the antigen. The same TCR was present in all of the positive microcultures. TCR evaluation carried out directly on blood lymphocytes by PCR amplification led to a similar frequency estimate after immunization, whereas the TCR was not found among 2.5 x 10(6) CD8(+) lymphocytes collected before immunization. Our results prove unambiguously that vaccines containing only a tumor-specific antigenic peptide can elicit a CTL response. Even though they provide no information about the effector mechanisms responsible for the observed reduction in tumor mass in this patient, they would suggest that low-level CTL responses can initiate tumor rejection.


Subject(s)
Antigens, Neoplasm , Cancer Vaccines/therapeutic use , Melanoma/immunology , Melanoma/therapy , Neoplasm Proteins/therapeutic use , T-Lymphocytes, Cytotoxic/immunology , Base Sequence , Cancer Vaccines/genetics , Clone Cells/immunology , Cytotoxicity, Immunologic , DNA Primers/genetics , Humans , Immunophenotyping , In Vitro Techniques , Melanoma/genetics , Melanoma/secondary , Neoplasm Proteins/genetics , Polymerase Chain Reaction , Receptors, Antigen, T-Cell, alpha-beta/genetics , Vaccination
4.
Cancer Res ; 61(10): 4078-83, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11358829

ABSTRACT

We have identified an antigen recognized on a human large cell carcinoma by an autologous tumor-specific CTL clone that was derived from mononuclear cells infiltrating the primary tumor. The antigenic peptide is presented by HLA-A2 molecules and is encoded by the alpha-actinin-4 gene, which is expressed ubiquitously. In the tumor cells, a point mutation generates an amino-acid change that is essential for recognition by the CTLS: The mutation was not found in alpha-actinin-4 cDNA sequences from about 50 lung carcinoma cell lines, suggesting that it is unique to this patient. Although he did not receive chemotherapy or radiotherapy, the patient has been without evidence of tumor since the resection of the primary lesion in 1996. Using tetramers of soluble HLA-A2 molecules loaded with the mutated antigenic peptide, anti-alpha-actinin-4 CTLs could be derived from blood samples collected from the patient in 1998 and 2000. It is possible that these CTLs, recognizing a truly tumor-specific antigen, play a role in the clinical evolution of this lung cancer patient.


Subject(s)
Actinin/genetics , Antigens, Neoplasm/genetics , Carcinoma, Large Cell/immunology , Epitopes, T-Lymphocyte/immunology , Lung Neoplasms/immunology , Microfilament Proteins , Point Mutation , T-Lymphocytes, Cytotoxic/immunology , Actinin/immunology , Aged , Antigens, Neoplasm/immunology , Carcinoma, Large Cell/genetics , DNA, Complementary/genetics , DNA, Neoplasm/genetics , Epitopes, T-Lymphocyte/genetics , HLA-A2 Antigen/genetics , HLA-A2 Antigen/immunology , Humans , Lung Neoplasms/genetics , Male , Peptide Fragments/immunology
5.
Cancer Res ; 61(9): 3718-24, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11325844

ABSTRACT

We have identified an antigen recognized by autologous CTL on the lung carcinoma cells of a patient who enjoyed a favorable clinical evolution, being alive 10 years after partial resection of the primary tumor. The antigenic peptide is presented by HLA-A2 molecules and encoded by a mutated sequence in the gene coding for malic enzyme, an essential enzyme that converts malate to pyruvate. In the tumor cell line derived from the patient, only the mutated malic enzyme allele is expressed, because of a loss of heterozygosity in the region of chromosome 6 that contains this locus. Tetramers of soluble HLA-A2 molecules loaded with the antigenic peptide stained approximately 0.4% of the patient's blood CD8 T cells. When these cells were stimulated in clonal conditions, 25% of them proliferated, and the resulting clones were lytic and specific for the mutated malic enzyme peptide. T-cell receptor analysis indicated that almost all of these antimalic CTLs shared the same receptor. Antimalic T cells were consistently found in blood samples collected from the patient between 1990 and 1999, at frequencies ranging from 0.1 to 0.4% of the CD8 cells. Their frequency appeared to double within 2 weeks after intradermal inoculation of lethally irradiated autologous tumor cells. These results indicate that nonmelanoma cancer patients may also have a high frequency of blood CTLs directed against a tumor-specific antigen.


Subject(s)
Antigens, Neoplasm/genetics , Antigens, Neoplasm/immunology , Carcinoma, Squamous Cell/immunology , HLA-A2 Antigen/immunology , Lung Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Antigen Presentation/immunology , Antigens, Neoplasm/blood , Base Sequence , Carcinoma, Squamous Cell/genetics , Chromosomes, Human, Pair 6 , DNA, Complementary/genetics , DNA, Neoplasm/genetics , Epitopes/immunology , HLA-A2 Antigen/blood , HLA-A2 Antigen/genetics , Humans , Loss of Heterozygosity , Lung Neoplasms/genetics , Malate Dehydrogenase/genetics , Malate Dehydrogenase/immunology , Male , Mice , Middle Aged , Molecular Sequence Data , Point Mutation , Transfection
6.
J Immunother ; 24(2): 172-83, 2001.
Article in English | MEDLINE | ID: mdl-11265775

ABSTRACT

The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUCI conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses. On this basis, three phase I trials were performed in patients with adenocarcinoma to evaluate the toxicity and the immunologic responses to mannan MUCI. Forty-one patients with metastatic or locally advanced carcinoma of the breast (trial 1), colon (trial 2), and various adenocarcinomas (trial 3) received increasing doses of M-FP (1 to 300 microg). The immunizations were given at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide (to increase cellular immunity) was given on weeks 1 and 4. M-FP was given intramuscularly in trial 1 and intraperitoneally in trial 2. No toxic effects occurred, and delayed-type hypersensitivity responses were present only as a microscopic lymphocytic infiltration. Overall, approximately 60% of the patients had high-titer MUC1 immunoglobulin G1 antibody responses, with the intraperitoneal route yielding approximately 10-fold higher responses. Cellular responses (proliferation, cytotoxic T cells, or CD8 T cells secreting tumor necrosis factor-alpha alphand interferon-gamma in response to MUC1 stimulation in vitro) were found in 28% of the patients, which was similar to that seen without cyclophosphamide. In most patients, disease progressed, but in five it remained stable. In addition, there were no objective responses. M-FP is not toxic and induces immune responses that were amplified by the intraperitoneal route of immunization. Cyclophosphamide was of no benefit.


Subject(s)
Cyclophosphamide/administration & dosage , Immunotherapy, Active , Mannans/immunology , Mucin-1/immunology , Neoplasms/therapy , Adenocarcinoma/immunology , Adenocarcinoma/therapy , Adult , Aged , Aged, 80 and over , Antibodies/blood , Breast Neoplasms/immunology , Breast Neoplasms/therapy , Colonic Neoplasms/immunology , Colonic Neoplasms/therapy , Cytotoxicity, Immunologic , Humans , Hypersensitivity, Delayed , Immunity, Cellular , Injections, Intramuscular , Injections, Intraperitoneal , Lymphocyte Activation , Mannans/administration & dosage , Mannans/genetics , Middle Aged , Mucin-1/administration & dosage , Mucin-1/genetics , Neoplasms/immunology , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/immunology , T-Lymphocytes/immunology
7.
Vaccine ; 18(28): 3297-309, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10869775

ABSTRACT

Mice immunised with human epithelial mucin MUC1 coupled to oxidised mannan produce MUC1 specific MHC Class 1 restricted CD8(+) cytotoxic T cells and are completely protected from the development of MUC1(+) tumours; such therapy may be applicable to humans. In this light we describe pre-clinical studies in cynomolgus monkeys (Macaca fascicularis), to test the efficacy of mannan-MUC1 in higher primates. Monkey MUC1 genomic clones were isolated from a macaque library, peptides and fusion protein synthesised and mice and monkeys immunised with macaque MUC1-mannan. In mice CTL responses were induced (as has been found with human MUC1 mannan conjugates), but in contrast monkeys produced a humoral response, with no T cell proliferative, cytotoxic responses or CTLp found. In spite of the presence of anti-MUC1 auto-antibodies, there was no toxicity or induction of autoimmunity.


Subject(s)
Mannans/immunology , Mucin-1/immunology , Amino Acid Sequence , Animals , Base Sequence , Cross Reactions , Exons , Immunization , Lymphocyte Activation , Macaca mulatta , Mice , Molecular Sequence Data , Mucin-1/chemistry , Mucin-1/genetics , Polymorphism, Genetic , T-Lymphocytes, Cytotoxic/immunology , Tandem Repeat Sequences
8.
Clin Cancer Res ; 6(3): 829-37, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10741704

ABSTRACT

The detection of tumor-specific T cells in immunized cancer patients usually relies on lengthy and difficult CTL assays; we now report on flow cytometry to detect the intracellular cytokines interleukin 2 (IL-2), IL-4, IFN-gamma, and tumor necrosis factor alpha (TNF-alpha) produced by CD4+CD69+ and CD8+CD69+ activated T cells after MUC1 antigen stimulation. Peripheral blood mononuclear cells were obtained from 12 patients with adenocarcinoma injected with mannan-MUC1; cells were exposed in vitro for 18 h to MUCI peptide in the presence of CD28 monoclonal antibody and Brefeldin; permeabilized cells were used for the expression of cytokines. After stimulation in vitro with MUC1-variable number of tandem repeats peptides, CD8+CD69+ T cells from all immunized patients generated 3-9 times higher levels of TNF-alpha(P < 0.038) and IFN-gamma (P <0.010) than did cells from 12 normal subjects; minor increases in IL-4 occurred. By contrast, CD4+CD69+ cells showed no overall alteration in TNF-alpha and IFN-gamma cytokine production, although in some patients, their measurement was informative; the measurement of IL-2 was not useful in either CD4+CD69+ or CD8+CD69+ cells. We conclude that in MUC1-immunized patients, the measurement of TNF-alpha and IFN-gamma in activated CD69+CD8+ T cells may be indicative of their immune status.


Subject(s)
Cytokines/metabolism , Immunotherapy , Mucin-1/immunology , Adenocarcinoma/therapy , Flow Cytometry , Humans , Immunization , Influenza Vaccines/pharmacology , Interferon-gamma/metabolism , Interleukin-2/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Mannans/immunology , Mucin-1/genetics , Phytohemagglutinins/pharmacology , Recombinant Fusion Proteins/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Tetanus Toxoid/pharmacology , Tumor Necrosis Factor-alpha/metabolism
9.
Immunology ; 97(2): 264-71, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10447741

ABSTRACT

Standard methods to generate autoimmune reactions in mice, by immunization with antigens emulsified with adjuvants, stimulate strong helper (CD4) T-cell and antibody responses but are not reported to induce cytolytic CD8 T cells. The aim of this study was to assess whether specific autoreactive CD8 T cells could be readily generated after immunization with a 'weak' autoantigen in adjuvant. Mice were immunized intraperitoneally three times with the E3 subunit of the mitochondrial 2-oxoacid dehydrogenase enzyme complexes (dihydrolipoamide dehydrogenase) emulsified with Freund's complete adjuvant. Splenic and lymph node lymphocytes were harvested after 14 days for in vitro functional studies. T lymphocytes were tested for proliferative responses and cytotoxicity against antigen-loaded isogeneic target cells. An autoreactive cytolytic T lymphocyte (CTL) response was detectable only after the in vitro restimulation of lymphocytes with E3 antigen-loaded syngeneic splenocytes. These CTL were identified as H-2-restricted CD8+ T cells. A proliferative response to E3 was demonstrable against antigen-pulsed syngeneic splenocytes. Immunized mice also generated strong antibody responses to E3. Liver histology showed portal infiltrates interpreted as a response of the liver to a non-specific immunological stimulus. It is concluded that autoreactive cytolytic T cells can be generated experimentally upon appropriate stimulation of the immune system, and can be identified in vitro upon release from the controlling mechanisms that are likely to regulate them in vivo.


Subject(s)
Autoimmunity , Dihydrolipoamide Dehydrogenase/immunology , Freund's Adjuvant , T-Lymphocytes, Cytotoxic/immunology , Animals , Cell Culture Techniques , Cell Division/immunology , Cytotoxicity, Immunologic , Female , Immunization , Liver/immunology , Liver/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C3H
10.
Vaccine ; 17(20-21): 2740-52, 1999 Jun 04.
Article in English | MEDLINE | ID: mdl-10418926

ABSTRACT

Mice immunised with oxidised mannan conjugated to the human mucin 1 (MUC1), produce MHC Class 1 restricted CD8+ cytotoxic T-cells which eradicate MUC1 + tumours, indicating potential for the immunotherapy of MUC1 + cancers in humans. We now describe preclinical studies performed in cynomolgus monkeys immunised with human or murine MUC1 conjugated to oxidised mannan, where immune responses and toxicity were examined. High titred antibodies specific for MUC1 were produced, MUC1 specific CD4+ and CD8+ T-cell proliferative responses and specific cytotoxic precursor cells (CTLp) were found, but not MUC1 specific cytotoxic T-cells (CTL). There was no toxicity and monkeys can be immunised against human MUC1 with mannan-MUC1 conjugates, but a humoral response (Th2 type) predominates. The results contrast with those obtained in mice when a CTL response (Th1 type) predominates.


Subject(s)
Mannans/immunology , Mucin-1/immunology , Amino Acid Sequence , Animals , Antibody Formation , Cyclophosphamide/pharmacology , Disaccharides/immunology , Epitope Mapping , Humans , Immunization , Lymphocyte Activation , Macaca fascicularis , Mice , Molecular Sequence Data , T-Lymphocytes, Cytotoxic/immunology , Tetanus Toxoid/immunology , Vaccines, Conjugate/immunology
11.
Tumour Biol ; 19 Suppl 1: 71-8, 1998.
Article in English | MEDLINE | ID: mdl-9422091

ABSTRACT

The binding affinity of a monoclonal antibody to its ligand has been often used as a qualitative and quantitative measure for the specificity of the antibody. The aim of this paper was to assess the affinity of binding to recombinant and synthetic MUC1 peptides of 52 monoclonal antibodies as part of the ISOBM TD-4 Workshop. Affinity of binding was assessed using a surface plasmon resonance biosensor (BIAcore). The monoclonal antibodies exhibited variable affinity to MUC1 peptides, and overall 25/52 antibodies showed significant binding to the test peptides with affinities ranging from 2.4 x 10(6) to 3.1 x 10(8) M-1. Affinities calculated by analysis of kinetic biosensor data agreed well with affinities determined by equilibrium binding analysis of radiolabelled antibodies. The affinity measurements may provide help when determining the use of various monoclonals in tumour biology research.


Subject(s)
Antibodies, Monoclonal/immunology , Antibody Affinity/immunology , Binding Sites, Antibody/immunology , Mucin-1/immunology , Peptide Fragments/immunology , Amino Acid Sequence , Humans , Molecular Sequence Data
12.
J Clin Invest ; 100(11): 2783-92, 1997 Dec 01.
Article in English | MEDLINE | ID: mdl-9389743

ABSTRACT

Mucin 1 (MUC1) is a large complex glycoprotein that is highly expressed in breast cancer, and as such could be a target for immunotherapy. In mice, human MUC1 is highly immunogenic, particularly when conjugated to mannan, where a high frequency of CD8(+) MHC-restricted cytotoxic T lymphocytes is induced, accompanied by tumor protection. On this basis, a clinical trial was performed in which 25 patients with advanced metastatic carcinoma of breast, colon, stomach, or rectum received mannan-MUC1 in increasing doses. After 4 to 8 injections, large amounts of IgG1 anti-MUC1 antibodies were produced in 13 out of 25 patients (with antibody titers by ELISA of 1/320-1/20,480). Most of the antibodies reacted to the epitopes STAPPAHG and PAPGSTAP. In addition, T cell proliferation was found in 4 out of 15 patients, and CTL responses were seen in 2 out of 10 patients. Mannan-MUC1 can immunize patients, particularly for antibody formation, and to a lesser extent, cellular responses. It remains to be seen whether such responses have antitumor activity.


Subject(s)
Adenocarcinoma/immunology , Antibodies/immunology , Breast Neoplasms/immunology , Cancer Vaccines/immunology , Colonic Neoplasms/immunology , Mannans/immunology , Mucin-1/immunology , Rectal Neoplasms/immunology , Stomach Neoplasms/immunology , T-Lymphocytes/immunology , Adenocarcinoma/physiopathology , Aged , Amino Acid Sequence , Breast Neoplasms/physiopathology , Cell Division , Colonic Neoplasms/physiopathology , Cytotoxicity Tests, Immunologic , Epitopes, B-Lymphocyte/immunology , Female , Humans , Immunoglobulin Isotypes , Male , Mannans/administration & dosage , Molecular Sequence Data , Mucin-1/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/immunology , Rectal Neoplasms/physiopathology , Stomach Neoplasms/physiopathology , T-Lymphocytes/cytology
13.
J Immunol ; 159(11): 5211-8, 1997 Dec 01.
Article in English | MEDLINE | ID: mdl-9548459

ABSTRACT

HLA-A*0201/Kb transgenic mice were immunized with oxidized mannan-mucin 1 (MUC1) as a fusion protein (containing five repeats of the 20-amino-acid MUC1 VNTR (variable number of tandem repeats) that generated highly active CD8+ CTLs to MUC1 peptides. In a direct CTL assay, the MUC1 peptides could be presented specifically by both the transgenic murine HLA-A*0201/Kb and human HLA-A*0201 molecules. The 9-mer MUC1 peptide sequences (APDTRPA and STAPPAHGV) were presented by HLA-A*0201, although they did not contain L at P2 and L/V at P9, the preferred motifs; as a consequence, the binding was of relatively low affinity when compared with a high affinity-binding HIV peptide (ILKEPVHGV). In addition, when mice were immunized separately with the HLA-A*0201-binding peptides (STAPPAHGV or APDTRPAP-containing peptides-keyhole limpet hemocyanin-mannan), direct lysis of MCF-7 (HLA-A*0201+, MUC1+) also occurred. The findings are of interest for tumor immunotherapy, particularly as the CTLs generated to low affinity-binding peptides were highly active and could specifically lyse an HLA-A*0201+ human breast cancer cell line without further in vitro stimulation. The findings demonstrate that the range of peptides that can generate CTLs is broader than formerly considered.


Subject(s)
Antigen Presentation , Breast Neoplasms/immunology , HLA-A2 Antigen/immunology , Mucin-1/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Cytotoxicity Tests, Immunologic , Epitopes , Humans , Mice , Mice, Transgenic , Minisatellite Repeats , Molecular Sequence Data , Peptides , Tumor Cells, Cultured
14.
J Gastroenterol Hepatol ; 10(5): 491-7, 1995.
Article in English | MEDLINE | ID: mdl-8963023

ABSTRACT

The aim of this study was to investigate liver histology in mice after immunization with the conserved self molecule dihydrolipoamide dehydrogenase, E3, a subunit of the mitochondrial 2-OADC enzyme family identified as the M2 autoantigen in the liver disease, primary biliary cirrhosis. Mice were immunized by a novel procedure. The autoantigen E3 was introduced by pinocytosis into hypertonically treated syngeneic lymphoid cells to facilitate intracellular antigen processing and presentation and the generation of a cytolytic T cell response. Liver sections were examined and scored for evidence of an inflammatory response by two independent procedures: standard microscopy with visual scoring, and automated scanning with computerized scoring. There was a close correlation between read-outs of liver histology by standard microscopy and automated scanning, using the index of mononuclear cellular infiltrations in hepatic portal tracts. Such infiltrates were prominent in the immunized mice, but, unexpectedly, the degree of infiltration was similar in mice injected with autoantigen (E3)-loaded syngeneic cells, or syngeneic cells treated only with hypertonic medium. The equivalent changes in the liver with the experimental and control protocol is indicative of the reactivity of the liver to any provocative immune stimulus, and is cautionary for protocols designed for the induction of autoimmune liver disease in experimental animals.


Subject(s)
Immunization , Liver Circulation , Lymphocytes/immunology , Portal System , Animals , Autoantigens/immunology , Autoimmune Diseases/pathology , Culture Media/pharmacology , Cytotoxicity Tests, Immunologic , Female , Hypertonic Solutions/pharmacology , Liver/drug effects , Liver/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Time Factors
15.
Cell Immunol ; 148(1): 166-76, 1993 Apr 15.
Article in English | MEDLINE | ID: mdl-8495485

ABSTRACT

We investigated whether a novel immunisation scheme using an endogenous protein could stimulate an autoreactive cytolytic response. The protein selected was porcine dihydrolipoamide dehydrogenase, the E3 component of the mitochondrial 2-OADC enzyme family, because it is structurally conserved in mammals and ubiquitously expressed. Recombinant insulin was used as an alternative antigen. Female BALB/c mice were injected with adjuvant-free syngeneic lymphoid cells that had been exposed to E3 in hypertonic medium to facilitate its pinocytosis and were given two booster injections. Effector lymphoid cells from immunised mice were cultured in vitro with irradiated syngeneic cells that had been treated with hypertonic medium, either with or without antigen. Cytolytic effector cells were detected that lysed isogeneic and not allogeneic target cells, but only from mice immunised with E3. This experimental system provides a new model for the early stages of the development of autoimmunity.


Subject(s)
Autoantigens/immunology , Autoimmunity , Histocompatibility Antigens/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Cell Line , Dihydrolipoamide Dehydrogenase/immunology , Female , Lymph Nodes/cytology , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Pinocytosis , Spleen/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...